Sarah Cannon Research Institute (SCRI), a global leader in conducting community-based clinical trials, has announced a collaboration with AstraZeneca to advance the delivery of oncology clinical trials through innovative technology and operational synergies. The partnership focuses on expediting timelines for clinical trials, reducing site burden, and increasing U.S. enrollment.
Genospace, a precision medicine platform, and SCRI Development Innovations have developed a proprietary technology that integrates data directly from the Electronic Health Record (EHR) to the Electronic Data Capture (EDC) system (EHR2EDC or E2E) for clinical trial data collection. This technology has already shown benefits by decreasing the time required for on-site data entry, reducing manual labor and monitoring costs, enhancing data quality, and speeding up overall clinical decision-making.
Central to the collaboration’s efforts is the new model from SCRI, which aims to synchronize end-to-end clinical research management across a vast network of physicians and sites, providing trial access to a significant portion of cancer patients in the U.S.
Dee Anna Smith, CEO of SCRI, emphasized the potential impact of improved research operations on the drug development industry, enabling faster introduction of novel therapies through a more extensive network of physicians and communities.
Michele Sample, Vice President of Clinical Operations in Oncology R&D at AstraZeneca, underscored the commitment to improving accessibility to trial participation and addressing the evolving needs of clinical trial execution. By streamlining the data collection process, the collaboration aims to diversify clinical trial participants and enhance the efficiency of trials in the U.S.
SCRI, with a rich history of advancing therapies for patients over the last three decades, has led groundbreaking drug development, conducting numerous first-in-human trials and contributing to the research behind the majority of new cancer therapies approved by the FDA. The joint venture with former US Oncology Research in 2022 was established to expand clinical trial access further nationwide.
This partnership between SCRI and AstraZeneca marks an ambitious step toward delivering new treatments to patients more efficiently while leveraging a comprehensive network of physician-researchers and trial sites across the United States.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
